Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer Corrigendum in /10.3892/or.2019.7120

Xi,Hong-Qing; Cui,Jian-Xin; Shen,Wei-Song; Wu,Xiao-Song; Bian,Shi‑Bo; Li,Ji-Yang; Song,Zhou; Wei,Bo; Chen,Lin

doi:10.3892/or.2014.3207

Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer

Corrigendum in: /10.3892/or.2019.7120

Authors:
- Hong-Qing Xi
- Jian-Xin Cui
- Wei-Song Shen
- Xiao-Song Wu
- Shi‑Bo Bian
- Ji-Yang Li
- Zhou Song
- Bo Wei
- Lin Chen
View Affiliations

Affiliations: Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing 100853, P.R. China
Published online on: May 22, 2014 https://doi.org/10.3892/or.2014.3207
Pages: 181-188

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5), a marker of adult stem cells and cancer stem cells, plays important roles in tumor progression. Furthermore, Lgr5 also contributes to chemoradiotherapy resistance. However, the function of Lgr5 in the prediction of preoperative chemotherapy efficacy has not been reported. We evaluated the potential of Lgr5 in predicting tumor response and overall survival in advanced gastric cancer treated with preoperative chemotherapy. The association between Lgr5 and chemotherapy resistance was also investigated in gastric cancer cell lines. Hematoxylin and eosin staining and immunohistochemical analysis of Lgr5 expression were performed in 68 cases of gastric cancer treated with preoperative chemotherapy. Lgr5 expression was specifically silenced in the AGS gastric cancer cell lines by RNA interference. Levels of Lgr5 mRNA and protein in cell lines were detected by quantitative reverse transcription-polymerase chain reaction or western blotting. Cell viability was evaluated by an MTT assay. Cell apoptosis was assessed by Annexin V-FITC/propidium iodide dual staining analysis. We found that Lgr5 expression was significantly associated with tumor regression grade after preoperative chemotherapy. The rate of positive Lgr5 expression was significantly higher in patients with poor tumor regression compared with those exhibiting tumor regression (P=0.001). Lgr5-positive patients had a significantly shorter survival time than Lgr5-negative patients (P=0.001). Inhibition of Lgr5 expression with small interfering RNA increased the sensitivity of AGS gastric cancer cells to chemotherapy. Our findings suggest that Lgr5 expression may be implicated in the chemoresistance of gastric cancer cells and is a potential novel biomarker for predicting response to chemotherapy and prognosis in gastric cancer patients, and may also represent a potential new therapeutic target for cancer therapy.

View Figures

View References

1	Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005. View Article : Google Scholar
2	Thun MJ, DeLancey JO, Center MM, Jemal A and Ward EM: The global burden of cancer: priorities for prevention. Carcinogenesis. 31:100–110. 2010. View Article : Google Scholar : PubMed/NCBI
3	Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 355:11–20. 2006. View Article : Google Scholar : PubMed/NCBI
4	Becker K, Langer R, Reim D, et al: Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 253:934–939. 2011. View Article : Google Scholar
5	Van der Flier LG, Sabates-Bellver J, Oving I, et al: The intestinal Wnt/TCF signature. Gastroenterology. 132:628–632. 2007.PubMed/NCBI
6	Segditsas S, Sieber O, Deheragoda M, et al: Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice. Hum Mol Genet. 17:3864–3875. 2008. View Article : Google Scholar : PubMed/NCBI
7	Yamamoto Y, Sakamoto M, Fujii G, et al: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology. 37:528–533. 2003. View Article : Google Scholar : PubMed/NCBI
8	Carmon KS, Lin Q, Gong X, Thomas A and Liu Q: LGR5 interacts and cointernalizes with Wnt receptors to modulate Wnt/β-catenin signaling. Mol Cell Biol. 32:2054–2064. 2012.PubMed/NCBI
9	Barker N, van Es JH, Kuipers J, et al: Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature. 449:1003–1007. 2007. View Article : Google Scholar : PubMed/NCBI
10	Jaks V, Barker N, Kasper M, et al: Lgr5 marks cycling, yet long-lived, hair follicle stem cells. Nat Genet. 40:1291–1299. 2008. View Article : Google Scholar : PubMed/NCBI
11	Barker N, Huch M, Kujala P, et al: Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro. Cell Stem Cell. 6:25–36. 2010.
12	Simon E, Petke D, Boger C, et al: The spatial distribution of LGR5⁺ cells correlates with gastric cancer progression. PLoS One. 7:e354862012.PubMed/NCBI
13	Takahashi H, Ishii H, Nishida N, et al: Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol. 18:1166–1174. 2011.
14	Kemper K, Prasetyanti PR, De Lau W, Rodermond H, Clevers H and Medema JP: Monoclonal antibodies against Lgr5 identify human colorectal cancer stem cells. Stem Cells. 30:2378–2386. 2012. View Article : Google Scholar : PubMed/NCBI
15	Wu XS, Xi HQ and Chen L: Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol. 10:2442012. View Article : Google Scholar : PubMed/NCBI
16	McClanahan T, Koseoglu S, Smith K, et al: Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors. Cancer Biol Ther. 5:419–426. 2006. View Article : Google Scholar : PubMed/NCBI
17	Tanese K, Fukuma M, Yamada T, et al: G-protein-coupled receptor GPR49 is up-regulated in basal cell carcinoma and promotes cell proliferation and tumor formation. Am J Pathol. 173:835–843. 2008. View Article : Google Scholar : PubMed/NCBI
18	Becker L, Huang Q and Mashimo H: Lgr5, an intestinal stem cell marker, is abnormally expressed in Barrett’s esophagus and esophageal adenocarcinoma. Dis Esophagus. 23:168–174. 2010.PubMed/NCBI
19	Nakata S, Campos B, Bageritz J, et al: LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. Brain Pathol. 23:60–72. 2013. View Article : Google Scholar : PubMed/NCBI
20	Vermeulen L, Todaro M, de Sousa Mello F, et al: Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci USA. 105:13427–13432. 2008. View Article : Google Scholar : PubMed/NCBI
21	Becker L, Huang Q and Mashimo H: Immunostaining of Lgr5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. ScientificWorldJournal. 8:1168–1176. 2008. View Article : Google Scholar : PubMed/NCBI
22	Saigusa S, Inoue Y, Tanaka K, et al: Clinical significance of LGR5 and CD44 expression in locally advanced rectal cancer after preoperative chemoradiotherapy. Int J Oncol. 41:1643–1652. 2012.PubMed/NCBI
23	Saigusa S, Inoue Y, Tanaka K, et al: Significant correlation between LKB1 and LGR5 gene expression and the association with poor recurrence-free survival in rectal cancer after preoperative chemoradiotherapy. J Cancer Res Clin Oncol. 139:131–138. 2013. View Article : Google Scholar
24	Ozkan M, Akbudak IH, Deniz K, et al: Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in advanced gastric cancer. Asian Pac J Cancer Prev. 11:181–185. 2010.PubMed/NCBI
25	Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
26	Becker K, Mueller JD, Schulmacher C, et al: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 98:1521–1530. 2003. View Article : Google Scholar : PubMed/NCBI
27	Xi HQ, Wu XS, Wei B and Chen L: Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol. 47:785–794. 2012. View Article : Google Scholar : PubMed/NCBI
28	Xi HQ, Zhao P and Han WD: Clinicopathological significance and prognostic value of LRP16 expression in colorectal carcinoma. World J Gastroenterol. 16:1644–1648. 2010. View Article : Google Scholar : PubMed/NCBI
29	Matsubara J, Yamada Y, Nakajima TE, et al: Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer. Oncology. 74:76–83. 2008. View Article : Google Scholar : PubMed/NCBI
30	Wood LD, Calhoun ES, Silliman N, et al: Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers. Hum Mutat. 27:1060–1061. 2006. View Article : Google Scholar : PubMed/NCBI
31	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C^_T method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
32	Lordick F, Stein HJ, Peschel C and Siewert JR: Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 91:540–551. 2004. View Article : Google Scholar
33	Al-Hajj M: Cancer stem cells and oncology therapeutics. Curr Opin Oncol. 19:61–64. 2007.PubMed/NCBI
34	Dirks PB: Cancer: stem cells and brain tumours. Nature. 444:687–688. 2006. View Article : Google Scholar : PubMed/NCBI
35	Setoguchi T, Taga T and Kondo T: Cancer stem cells persist in many cancer cell lines. Cell Cycle. 3:414–415. 2004. View Article : Google Scholar : PubMed/NCBI
36	Haq R and Zanke B: Inhibition of apoptotic signaling pathways in cancer cells as a mechanism of chemotherapy resistance. Cancer Metastasis Rev. 17:233–239. 1998. View Article : Google Scholar : PubMed/NCBI
37	Gu L, Findley HW, Zhu N and Zhou M: Endogenous TNFalpha mediates cell survival and chemotherapy resistance by activating the PI3K/Akt pathway in acute lymphoblastic leukemia cells. Leukemia. 20:900–904. 2006. View Article : Google Scholar : PubMed/NCBI
38	Mahon KL, Henshall SM, Sutherland RL and Horvath LG: Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer. 18:R103–R123. 2011. View Article : Google Scholar : PubMed/NCBI
39	Cui J, Jiang W, Wang S, Wang L and Xie K: Role of Wnt/β-catenin signaling in drug resistance of pancreatic cancer. Curr Pharm Des. 18:2464–2471. 2012.
40	Zhang H, Zhang X, Wu X, et al: Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 323:106–113. 2012.PubMed/NCBI